Clinical Trial Update: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TQB2102 for injection is underway for HER2-positive biliary tract cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Biliary Tract Cancer | Phase 1, Phase 2 | Status: RECRUITING